Choose a folder
DISCOVER reveals new trends in metformin discontinuation in 11 452 patients – EASD 2017
Professor Kamlesh Khunti of the DISCOVER Scientific Committee presented an exciting new analysis of metformin discontinuation from the DISCOVER study at the 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD) on 11–15 September in Lisbon, Portugal.
Despite recommendations from clinical guidelines, over one third of DISCOVER patients discontinued metformin upon initiation of second-line therapy. In total, 3961 patients (34.6%) discontinued metformin when initiating second-line therapy and metformin discontinuation varied greatly across regions (across region range: 22.0–67.1%). Factors associated with increased odds of metformin discontinuation included having chronic kidney disease and experiencing side effects.
A second novel analysis was also presented at EASD 2017 in a poster describing treatment reality versus guidelines in patients with type 2 diabetes initiating second-line treatment. There were also three encore presentations from the DISCOVER Scientific Committee on glycaemic control, vascular complications and treatment patterns. More information about these presentations can be found on the DISCOVER website here.
Thank you to all the DISCOVER investigators for their hard work which made these presentations possible. For further updates, please keep visiting the DISCOVER website.
Approval ID: Z4-7480 Date of preparation: 12 October 2017 Date of expiry: 12 October 2018